Clinical trials: Oligometastatic Breast Carcinoma
Oligometastatic Breast Carcinoma, Breast Cancer
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
The purpose of this study is to see if using Stereotactic Body Radiation Therapy/SBRT to treat a single metastatic site where cancer has worsened may be an effective treatment for people with oligometastatic breast cancer.
- Conditions
- Oligometastatic Breast Carcinoma, Breast Cancer, Metastatic Breast Cancer, Metastatic Breast Carcinoma
- Trial name
- NCT05534438
- Testing
- Stereotactic body radiotherapy
- Where
- 8 sites in United States
- Volunteers
- 46 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Local Therapy for ER/PR-positive Oligometastatic Breast Cancer
Randomized phase 2 trial to evaluate the efficacy of local therapy for oligometastasis from ER/PR-positive breast cancer. The study hypothesis is that local therapy in addition to systemic therapy improves progression-free…
- Trial name
- LARA (NCT04698252)
- Testing
- Radiotherapy, Surgery, Radiofrequency ablation
- Where
- Brazil
- Volunteers
- 74 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Breast Neoplasm Malignant Female
SBRT for Breast Cancer Oligometastases
This is a prospective data collection of treatment outcome for newly diagnosed oligometastatic breast cancers with 1-3 bone metastases. Eligible patients will be identified from the weekly Breast MDC.
- Trial name
- NCT04424732
- Testing
- Stereotactic Body Radiotherapy
- Where
- Jordan
- Volunteers
- 50 people
- Sponsor
- King Hussein Cancer Center
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma
Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
This randomized phase II/III trial studies how well standard of care therapy with stereotactic radiosurgery and/or surgery works and compares it to standard of care therapy alone in treating patients with breast cancer that has…
- Conditions
- Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Liver
- Trial name
- NCT02364557
- Testing
- Stereotactic Body Radiotherapy, Surgery
- Where
- 162 sites in United States, Canada and 2 more
- Volunteers
- 129 people
- Sponsor
- NRG Oncology
TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
The purpose of this study is determine if receiving stereotactic body radiation(SBRT) when participants' metastatic tumors have just begun to grow increase the length of time before disease gets worse
- Conditions
- TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer, NSCLC, NSCLC Stage IV
- Trial name
- NCT03808662
- Testing
- Sterotactic Body Radiotherapy/SBRT, Standard of care
- Where
- 10 sites in United States, Canada
- Volunteers
- 107 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Breast Cancer, HER2-positive Breast Cancer
A Study of Surgery and Radiotherapy in People With Breast Cancer
The researchers are doing this study to see if the combination of surgery, locoregional radiation therapy, SBRT (stereotactic body radiation therapy), and the usual approach is more effective in treating oligometastatic…
- Trial name
- NCT07053085
- Testing
- Lumpectomy or mastectomy, Radiotherapy, Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugs
- Where
- 7 sites in United States
- Volunteers
- 178 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Neoplasms, Bone Neoplasms
Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475
This is a prospective, observational pilot study that will describe the safety profile and biological effects of combining stereotactic ablative body radiosurgery (SABR) treatment (20Gy/1#) and a PD-1 antibody, MK-3475.
- Trial name
- BOSTON II (NCT02303366)
- Testing
- Stereotactic Ablative Body Radiosurgery (SABR), MK-3475
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Breast Cancer Stage IV, Oligometastatic Disease
Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
TAORMINA is an international, multicentre, randomised phase 3 trial for patients with oligometastatic breast cancer (OMBC) that will be allocated to combined stereotactic ablative radiotherapy (SABR) + systemic therapy…
- Trial name
- TAORMINA (NCT05377047)
- Testing
- SABR
- Where
- 19 sites in Ireland, Israel and 4 more
- Volunteers
- 345 people
- Sponsor
- Vastra Gotaland Region
Breast Cancer, Prostate Cancer
OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)
The goal of this clinical trial is to evaluate single-fraction metastases-directed SBRT in the broader radiation oncology community and to compare its safety and efficacy profile with the current Standard of Care (SoC) of…
- Conditions
- Breast Cancer, Prostate Cancer, NSCLC, Colorectal Cancer
- Trial name
- SPRINT (NCT06462963)
- Testing
- single-fraction SBRT, multiple-fraction SBRT
- Where
- 15 sites in Belgium, Italy and 2 more
- Volunteers
- 302 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Oligometastatic Breast Carcinoma, Radiomics
FDG PET/CT Radiomics for True Oligometastatic Breast Cancer
FDG PET CT Radiomics for True Oligometastatic Breast Cancer
- Trial name
- NCT07872332
- Volunteers
- 100 people
- Sponsor
- Sohag University
Breast Cancer, Metastatic Cancer
Metastases Directed Therapy for Oligometastatic Breast Cancer
This is a phase III randomized study evaluating the benefit from adding metastases directed therapy and locoregional treatment of the primary in breast cancer patients diagnosed with de novo oligometastatic disease patients will…
- Conditions
- Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer
- Trial name
- NCT06144346
- Testing
- Stereotactic Ablative Radiation Therapy, Locoregional treatment, Standard of Care
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute, Egypt
Metastatic Breast Cancer
Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer
The prognosis for patients with metastatic breast cancer has improved continuously. Systemic therapies alone are not able to cure the disease permanently.
- Trial name
- OLIGOMA (NCT04495309)
- Testing
- Metastases-directed Radiotherapy
- Where
- 14 sites in Germany
- Volunteers
- 87 people
- Sponsor
- University Hospital Schleswig-Holstein
Breast Cancer, Oligometastasis
stereOtactic Body RadIothErapy for exTracranial oligomeTastAtic Breast Cancer: Multi Institutional Retrospective Database
Oligometastatic breast cancer is a condition in which breast cancer has spread to a small number of other parts of the body. Patients with this type of disease may live longer than those with more widespread metastases.
- Trial name
- ORIETTA (NCT07397585)
- Where
- 28 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Istituto Clinico Humanitas
Breast Cancer, Metastasis to Liver
Study on SBRT for Inoperable Lung and Liver Oligometastases From Breast Cancer
Investigators designed a phase II study to evaluate safety and efficacy of lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients unsuitable for surgery, using VMAT RapidArc approach.
- Conditions
- Breast Cancer, Metastasis to Liver, Metastasis to Lung
- Trial name
- NCT02581670
- Testing
- stereotactic radiation therapy (SRT)
- Where
- Italy
- Volunteers
- 65 people
- Sponsor
- Istituto Clinico Humanitas
HER2-positive Breast Cancer
Basket Study for Oligo-metastatic Breast Cancer
The study will include patients with HER2-positive breast cancer and 1- 3 distant metastatic lesions, all amenable for curative intervention. Patients will be stratified by prior therapy and ER expression.
- Trial name
- ANISE (NCT05982678)
- Testing
- Trastuzumab deruxtecan
- Where
- Netherlands
- Volunteers
- 72 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer Metastatic
Radiotherapy for Extracranial Oligometastatic Breast Cancer
More and more evidence suggests that local radiotherapy can improve the outcomes for patients with oligometastatic disease. The purpose of this study is to assess the impact of radiotherapy, compared with standard systemic…
- Trial name
- NCT04646564
- Testing
- standard of care, radiotherapy + standard of care
- Where
- 2 sites in China
- Volunteers
- 170 people
- Sponsor
- Chinese Academy of Medical Sciences
HER2-positive Metastatic Breast Cancer, Oligometastatic Disease
Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer
This study involves two non-randomized groups of patients: the observation group and the comparison group. The comparison group will retrospectively include data on 29 patients with oligometastatic HER2-positive breast cancer who…
- Trial name
- NCT06299852
- Testing
- Trastuzumab emtansine
- Where
- Russia
- Volunteers
- 58 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
This phase III trial evaluates the effect of adding locoregional therapy (surgery and radiation) and metastasis-directed stereotactic body radiation therapy (SBRT) to standard systemic therapy following standard HER2-targeted…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Oligometastatic Breast Carcinoma
- Trial name
- NCT07578116
- Testing
- Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment
- Where
- 59 sites in United States
- Volunteers
- 562 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer, MRD
Observational Clinical Study on Role of MRD in Predicting Local Therapy in Oligometastatic Breast Cancer
This is an observational clinical study of MRD as a predictor of local treatment in patients with oligometastatic breast cancer.
- Trial name
- NCT06918262
- Testing
- local treatment
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Hospital of Jilin University
Breast Cancer, Metastatic, Metastatic Breast Cancer
Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II
The goal of this clinical trial is to assess Stereotactic Ablative Radiotherapy (SABR) as a method to delay a change in systemic therapy in patients with oligoprogressive ER-positive, HER2-negative advanced breast cancer.
- Trial name
- AVATARII (NCT06882499)
- Testing
- Stereotactic Ablative Radiotherapy, Physician's choice of systemic treatment
- Volunteers
- 74 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia